Innovation in Industry with Sean Bohen, MD

In this episode, host Shikha Jain, MD, speaks with Sean Bohen, MD, about how cancer therapies are changing how oncology can be discussed, shifting from clinical to industry work and more. •    Welcome to another exciting episode of Oncology Overdrive :58 •    About Bohen 1:04 •    The interview 1:30     •    Tell us about your journey. How did you become an oncologist, and how did you make the transition into working in the pharmaceutical industry?  1:51 •    How did you end up at Olema Oncology after working with other pharmaceutical companies? What was your decision-making process to focus on the industry part of your career? 3:44 •    Tell us more about what Olema Oncology does and what your role is there. 6:30 •    What do you see coming down the pipeline for breast cancer research and innovation? … What do you think Olema will contribute to that space? 8:58 •    Bohen and Jain on the ways in which new treatments have resulted in shifting conversations around cancer care and patient quality of life.  12:45 •    If someone in fellowship is interested in working in industry, pharmaceuticals or scientific development, what are the most effective ways to get into this space? 18:21 •    Jain and Bohen on changing the mindset and misconceptions around moving between clinical, academic and industry work within the field and after fellowship. 20:52 •    What do you see happening in the oncology landscape twenty years from now?  25:46 •    If someone could only listen to the last two minutes of this episode, what would you want them to take away? 29:19 •    How to contact Bohen 30:54 •    Thanks for listening 31:52 Sean Bohen, MD, is the President and CEO of Olema Oncology.

We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Bohen can be reached at olema.com.   Disclosures: Jain and Bohen report no relevant financial disclosures.